Mariani Stefania, Fiore Daniela, Persichetti Agnese, Basciani Sabrina, Lubrano Carla, Poggiogalle Eleonora, Genco Alfredo, Donini Lorenzo Maria, Gnessi Lucio
Department of Experimental Medicine, Section of Medical Physiopathology and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy.
Department of Surgical Sciences, Surgical Endoscopy Unit, Sapienza University of Rome, Rome, Italy.
Obes Surg. 2016 Jun;26(6):1215-20. doi: 10.1007/s11695-015-1859-4.
Sirtuins (SIRTs), ubiquitous deacetylases, are main regulators of energy homeostasis and metabolism. SIRT1 has a positive impact on obesity, diabetes mellitus, liver steatosis, and other metabolic disorders. Lean subjects have higher expression of SIRT1 in the adipose tissue compared to obese. However, it is not known whether weight loss associates with changes in blood SIRT1. We evaluated the effect of weight loss on circulating SIRT1, metabolic parameters, and body composition.
Thirty-two obese subjects were studied before and 6 months after BioEnterics® Intragastric Balloon (BIB®) [22 patients, BMI 41.82 ± 6.28 kg/m(2)] or hypocaloric diet [10 patients, BMI 38.95 ± 6.90 kg/m(2)]. Plasma SIRT1, body composition, measures of metabolic syndrome (waist circumference, fasting plasma glucose, blood pressure, HDL cholesterol, triglycerides), and inflammation markers (ESR, CRP, fibrinogen) were recorded.
SIRT1 levels showed a significant increase, together with a significant reduction of BMI, excess body weight, and total fat mass either after BIB or diet intervention. The percent excess body weight loss was 33.73 ± 19.06 and 22.08 ± 11.62 % after BIB and diet, respectively, a trend toward a metabolic and inflammatory amelioration was observed with both treatments. Negative correlation between SIRT1 and % fat mass (BIB, ρ = -0.537, p = 0.017; diet, ρ = -0.638, p = 0.047) was also seen.
The reduction of fat mass associates with increased plasma SIRT1 indicating that, besides tissue levels, circulating SIRT1 is stimulated by a negative caloric balance. The rise of plasma SIRT1 may represent a parameter associating with fat loss rather than weight lowering regardless of the weight reduction system method used.
沉默调节蛋白(SIRTs)是普遍存在的去乙酰化酶,是能量稳态和代谢的主要调节因子。SIRT1对肥胖、糖尿病、肝脂肪变性及其他代谢紊乱有积极影响。与肥胖者相比,瘦人脂肪组织中SIRT1的表达更高。然而,体重减轻是否与血液中SIRT1的变化相关尚不清楚。我们评估了体重减轻对循环SIRT1、代谢参数和身体成分的影响。
对32名肥胖受试者在接受BioEnterics®胃内球囊(BIB®)治疗前及治疗后6个月[22例,体重指数(BMI)41.82±6.28kg/m²]或低热量饮食治疗前及治疗后6个月[10例,BMI 38.95±6.90kg/m²]进行研究。记录血浆SIRT1、身体成分、代谢综合征指标(腰围、空腹血糖、血压、高密度脂蛋白胆固醇、甘油三酯)及炎症标志物(红细胞沉降率、C反应蛋白、纤维蛋白原)。
BIB或饮食干预后,SIRT1水平显著升高,同时BMI、超重体重和总脂肪量显著降低。BIB和饮食治疗后超重体重减轻百分比分别为33.73±19.06%和22.08±11.62%,两种治疗均观察到代谢和炎症改善的趋势。还观察到SIRT1与脂肪量百分比之间呈负相关(BIB治疗,ρ=-0.537,p=0.017;饮食治疗,ρ=-0.638,p=0.047)。
脂肪量减少与血浆SIRT1升高相关,表明除了组织水平外,负热量平衡可刺激循环SIRT1。无论采用何种减重系统方法,血浆SIRT1升高可能代表与脂肪减少相关而非体重降低的一个参数。